Bristol-Myers Squibb has announced its new-look leadership after the Celgene takeover goes through, and it reveals a mixed bag of new hires, sideways moves, and departures. The headline news is that ...

After delaying a late-stage readout last year due to “irregularities” at certain study sites, pivotal data for Bristol Myers ...

Five immunology assets in-licensed from BMS with potential to address unmet needs for patients with autoimmune diseases, including late-stage asset for lupus Bain Capital leads $300 million financing ...

Bristol Myers Squibb’s growth portfolio is offsetting declines in older products as planned, even as star heart drug Camzyos ...

Bristol Myers Squibb has called time on a bispecific antibody partnership with Zymeworks that the Big Pharma inherited from ...

BMS is looking to Phase III readouts from potential Eliquis successor, milvexian and schizophrenia med, Cobenfy to drive ...

After years serving as a rumored target of Big Pharma M&A, Mirati Therapeutics has finally made its sale a reality. The buyer, Bristol Myers Squibb, will pay up to $5.8 billion for the ...

As Bristol Myers Squibb works to build its treatment for a heart condition that can cause difficulty breathing into a blockbuster drug, it’s propped up an algorithm designed to help find more people ...

As the global energy landscape undergoes a rapid transition toward electrification and sustainable storage, the 2026 World Battery & Energy Storage Industry Expo (WBE) serves as a pivotal stage for ...

BMS Group, an independent insurance and reinsurance broker, has adopted mea Platform's broking operations products, which are ...